Nicholas Pace compensation by year
Accendra Health Summary Compensation Table · all 5 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Salary | $470,000 | $484,492 | $508,751 | $514,537 | $525,731 |
| Bonus | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $1,050,020 | $700,006 | $700,498 | $1,200,000 | $1,278,152 |
| Option awards | $0 | $0 | $0 | $0 | $0 |
| Non-equity incentive | $150,800 | $368,068 | $368,068 | $824,000 | $89,040 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $75,128 | $27,952 | $22,807 | $38,572 | $36,541 |
| Total | $1,745,948 | $1,580,518 | $1,600,124 | $2,577,109 | $1,929,464 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Accendra Health Inc DEF 14A filed March 29, 2023, accession 0001193125-23-083640, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Accendra Health Inc filed document, accession 0001193125-23-083640. Every figure is read from that document and cited to the page and table it appears in. Filed March 29, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 96,552 | $1,885,661 | — |
| PSU | 35,150 | $686,480 | — |
| PSU | 30,396 | $593,634 | — |
| RSU | 15,932 | $311,152 | — |
| RSU | 15,198 | $296,817 | — |
| RSU | 11,600 | $226,548 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Accendra Health Inc's FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2022 proxy (filed March 29, 2023)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2023-05-15 | Tax withholding | — | 4,947 | $18.73 | 267,095 |
| 2023-05-11 | Tax withholding | — | 7,186 | $18.39 | 272,042 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Accendra Health’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Edward Pesicka | President & Chief Executive Officer | $6,245,259 |
| Daniel Starck | Executive Vice President, President, Patient Direct & Chief Executive Officer of Apria, Inc. | $5,124,951 |
| Andrew Long | Executive Vice President, Chief Executive Officer, Products & Healthcare Services, Former Executive Vice President & Chief Financial Officer | $3,064,459 |
| Jeffrey Jochims | Former Executive Vice President, Chief Operating Officer & President, Products & Healthcare Services | $2,865,197 |
| Tammy Gomez | Executive Vice President & Chief Human Resources Officer | $2,834,407 |
| Nicholas Pace · this page | Executive Vice President, General Counsel & Corporate Secretary | $1,929,464 |
| Alexander Bruni | Executive Vice President & Chief Financial Officer | $875,361 |
The full Accendra Health compensation record
free company briefThis page is one person within Accendra Health's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Accendra Health proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Accendra Health's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.